Immune therapy for HR-positive, HER2-negative metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman age 18 to 75
- Have breast cancer that is HR-positive (ER and/or PR positive) and HER2-negative (no HER2 amplification on testing)
- Have locally advanced cancer that can’t be fully treated with surgery/radiation, or have recurrent metastatic cancer
- Have measurable disease on scan (or certain bone lesions) that can be tracked over time
- No prior chemotherapy or targeted therapy for metastatic disease; and you can start while meeting blood count, liver, and kidney function needs
- Not currently have cancer in the brain that is untreated or actively worsening, and you should not be on recent chemo/radiation/immunotherapy/surgery for metastatic disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This study tests combining a special heat treatment (thermal therapy) with immunotherapy to see if it works better for HER2-negative breast cancer that has spread to the liver. It may help people who have already tried other treatments and whose cancer has gotten worse.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a combination of two drugs—SHR-A1921 (a targeted therapy) and Adebrelimab (an immunotherapy)—for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, PD-L1 positive). It aims to see if this combo can help when hormone therapy and chemotherapy haven't worked well enough.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.